BCRX icon

BioCryst Pharmaceuticals

115 hedge funds and large institutions have $283M invested in BioCryst Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 37 increasing their positions, 35 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

more call options, than puts

Call options by funds: $ | Put options by funds: $

more funds holding in top 10

Funds holding in top 10:

more repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

less funds holding

Funds holding:

6% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 17

1.42% less ownership

Funds ownership: 90.83%89.41% (-1.4%)

25% less capital invested

Capital invested by funds: $380M → $283M (-$96.8M)

Holders
115
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$1.02M
Puts
$185K
Net Calls
Net Calls Change

Top Buyers

1 +$9.34M
2 +$7.16M
3 +$4.66M
4
CS
Credit Suisse
Switzerland
+$2.93M
5
UBS Group
UBS Group
Switzerland
+$2.39M

Top Sellers

1 -$10.1M
2 -$5.48M
3 -$5.11M
4
BBA
Baker Bros. Advisors
New York
-$4.75M
5
SSA
Schonfeld Strategic Advisors
New York
-$3.79M
Name Holding Trade Value Shares
Change
Change in
Stake
1
$36.5M
2
$27.5M
3
$27.3M
4
$22.2M
5
$17.1M
6
$13.9M
7
$11M
8
$9.34M
9
$8.7M
10
$8.24M
11
$8.14M
12
$7.95M
13
$7.76M
14
$5.12M
15
$4.75M
16
$4.66M
17
$4.3M
18
$4.25M
19
$3.92M
20
$3.58M
21
$3.36M
22
$2.99M
23
$2.61M
24
$2.51M
25
$2.36M